内蒙古乌兰察布地区布鲁氏菌体外药物敏感性及耐药机制分析

doi:10.3969/j.issn.1002-2694.2019.00.043

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (2577 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The aims of this study is to investigate the antibiotics susceptibilities profiles of Brucella strains obtained from Ulanqab of Inner Mongolia. The susceptibilities of 85 B.melitensis strains to 13 common used antibiotics was detected by E-test method, and resistance mechanism of rifampin and azithromycin were preliminarily examined. Subsequently, susceptibility of 149 B. melitensis strains from China to cotrimoxazole and rifampin were tested using K-B method. The study found that the number of strains resistance to azithromycin, cotrimoxazole and rifampin was 100% (85/85),7.0% (6/85) and 1.0% (1/85), respectively. All of the tested isolates were susceptible to minocycline, sparfloxacin, doxycycline, tetracycline, streptomycin, gentamicin, levofloxacin, ciprofloxacin, cefotaxime and cefoperazone sulbactam. Of them, aparfloxacin and minocycline shows the lowest MIC₉₀ value (0.032 μg/mL). The polymorphism of 2632 base T/C in the 23S rRNA of Brucella spp. was a potential molecular mechanism of B. melitensis in this study resistant to azithromycin. K-B method screen data indicated that all of 149 strains were susceptible to rifampin. Moreover, 25.5% (38/149) of strains were resistance to cotrimoxazole and these resistance strains were distributed in 18 different provinces of China. In conclusion, the situation of antibiotics resistance of B. melitensis clinical isolates was rather serious in Ulanqab region, surveillance of changes in antibiotic susceptible should be regular implemented. Moreover, we suggest that both minocycline and sparfloxacin could be as first-line agents for treatment of brucellosis.

Key words： B.melitensis drug susceptibility resistance mechanism

Received: 08 August 2018

R378.5

Fund:Supported by Nation Infectious Importance Special Fund (No. 2017ZX10303401), Bio-Safety key Special Fund (No. 2017YFC1200303), Bio-Safety key Special Fund (No. 2016YFC1200701),Nature Science Fund of Inner Mongolia Autonomy Region (No. 2018MS08004)

Corresponding Authors: LI Zhen-jun, Emial:LiZhenjun@icdc.cn

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Zhi-guo
	WANG Miao
	LI Xiao-yan
	TA Na
	ZHAO Hong-yan
	PIAO Dong-ri
	ZHAO Zhong-zhi
	LI Zhen-jun

Cite this article:

LIU Zhi-guo,WANG Miao,LI Xiao-yan等. In vitro drugs susceptibility and resistance mechanism investigation of Brucella isolates from Ulanqab region of Inner Mongolia[J]. Chinese Journal of Zoonoses, 2019, 35(5): 393-398.

URL:

http://www.rsghb.cn/EN/10.3969/j.issn.1002-2694.2019.00.043 OR http://www.rsghb.cn/EN/Y2019/V35/I5/393

[1] Pappas G, Papadimitriou P, Akritidis N, et al.The new global map of human brucellosis[J]. Lancet Infect Dis, 2006,6(2):91-99.DOI:10.1016/S1473-3099(06)70382-6
[2] Bayram Y, Korkoca H, Aypak C, et al.Antimicrobial susceptibilities of Brucella isolates from various clinical specimens[J]. Int J Med Sci, 2011, 8(3):198-202. DOI:10.7150/ijms.8.198
[3] Garcia-Rodriguez JA, Garcia SJ, Trujillano I.Lack of effective bactericidal activity of newquinolones against Brucella spp[J]. Antimicrob Agents Chemother, 1991, 35(4):756-759.DOI:10.1128/AAC.35.4.756
[4] Tien N, Sung YJ, Chang YC, Y et . The medical diagnostic approaches with phylogenetic analysis for rare Brucella spp. diagnosis in Taiwan[J]. Biomedicine (Taipei), 2015, 5(2):9. DOI: 10.7603/s40681-015-0009-6
[5] Wang Y, Zhang W, Ke Y, et al.Human brucellosis, a heterogeneously distributed, delayed, and misdiagnosed disease in china[J]. Clin Infect Dis, 2013, 56(5):750-751.DOI:10.1093/cid/cis980
[6] Parlak M, Guducuoglu H, Bayram Y, et al.Identification and determination of antibioticsusceptibilities of Brucella strains isolated from patients in van, Turkey by conventional and molecular methods[J]. Int J Med Sci, 2013,10(10):1406-1411.DOI:10.7150/ijms.6565
[7] Baykam N, Esener H, Ergonul O, et al.In vitro antimicrobial susceptibility of Brucella species[J]. Int J Antimicrob Agents, 2004, 23(4):405-407. DOI:10.1016/j.ijantimicag.2003.09.024
[8] Barbosa PR, Reinato SA, Pinto DSMJ, et al.Reduced susceptibility to rifampicin and resistance to multiple antimicrobial agents among Brucella abortus Isolates from Cattle in Brazil[J]. PLoS One, 2015, 10(7): e132532. DOI:10.1371/ journal. pone.0132532
[9] Sayan M, Kilic S, Uyanik MH.Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey[J]. J Infect Chemother, 2012, 18(1): 41-46.DOI: 10.1007/s10156-011-0281-7
[10] Kinsara A, Al-Mowallad A, Osoba AO.Increasing resistance of Brucellae to co-trimoxazole[J]. Antimicrob Agents Chemother, 1999, 43(6):1531.
[11] 刘志国,王妙,刘日宏,等.内蒙古自治区乌兰察布市羊种布鲁氏菌HOOF基因分型特征[J].中华流行病学杂志, 2017, 38(7):954-958.DOI: 10.3760/cma.j.issn.0254-6450.2017.07.021
[12] Marianelli C, Ciuchini F, Tarantino M, et al.Genetic bases of the rifampin resistance phenotype in Brucella spp[J]. J Clin Microbiol, 2004, 42(12):5439-5443. DOI: 10.1128 /JCM.42.12.5439-5443.2004
[13] Gür D, Kocagõz S, Akova M, et al.Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis[J]. Antimicrob Agents Chemother, 1999, 43(9):2337.
[14] Abdel-Maksoud M, House B, Wasfy M, et al.In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance[J]. Ann Clin Microbiol Antimicrob, 2012, 11(1):24-24. DOI: 10.1186/1476-0711-11-24
[15] López-Merino A, Contreras-Rodríguez A, Migranas-Ortiz R,et al.Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis[J].Scand J Infect Dis, 2004, 36(9):636-638.DOI:10.1080/00365540410020767
[16] ILhan Z, Solmaz H, Ekin IH.In vitro antimicrobial susceptibility of Brucella melitensis isolates from sheep in an area endemic for human brucellosis in Turkey[J]. J Vet Med Sci, 2013,75(8):1035-1040.DOI:10.1292/jvms.12-0163.
[17] Gattringer KB, Suchomel M, Eder M, et al.Time-dependent effects of rifampicin on Staphylococcal biofilms[J].Int J Artif Organs, 2010, 33(9):621-626.DOI: 10.1177/039139881003300907
[18] Hashim R, Ahmad N, Mohamed ZJ, et al.Identification and in vitro antimicrobial susceptibility of Brucella species isolated from human brucellosis[J]. Int J Microbiol, 2014, 2014:596245. DOI:10.1155/2014/596245
[19] Rahil AI, Othman M, Ibrahim W, et al.Brucellosis in Qatar: A retrospective cohort study[J]. Qatar Med J, 2014, 16(1):25-30. DOI:10.5339/qmj.2014.4
[20] Colmenero JD, Fernandez-Gallardo LC, Agundez JA, et al.Possible implications of doxycycline-rifampin interaction for treatment of brucellosis[J]. Antimicrob Agents Chemother, 1994, 38(12):2798-2802. DOI:10.1128/AAC.38.12.2798
[21] Arabi H, Pakzad I, Nasrollahi A, et al.Sulfonamide resistance genes (sul) M in extended spectrum beta lactamase (ESBL) and Non-ESBL producing escherichia coli isolated from Iranian hospitals[J]. Jundishapur J Microbiol, 2015, 8(7): e19961.DOI:10.5812/jjm.19961v2
[22] Huovinen P, Sundstrõm L, Swedberg G, et al.Trimethoprim and sulfonamide resistance[J]. Antimicrobial Agents and Chemotherapy, 1995, 39(2):279-289.
[23] Agwuh KN, Macgowan A.Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines[J]. J Antimicrob Chemother, 2006, 58(2):256-265. DOI:10.1093/jac/dkl224
[24] Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis[J]. PLoS One, 2012, 7(2): e32090. DOI: 10.1371/journal.pone.0032090
[25] Akova M, Gür D, Livermore DM, Kocagõz T, et al.In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs[J]. Antimicrob Agents Chemother, 1999, 43(5):1298-300.